Hepatitis D (HDV) - Drug Pipeline Landscape, 2022

Hepatitis D, also known as delta hepatitis, is an inflammation of the liver caused by the hepatitis D virus (HDV), which requires HBV for its replication. Hepatitis D infection cannot occur in the absence of hepatitis B virus. HDV-HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression towards hepatocellular carcinoma and liver-related death.

The primary route of transmission for hepatitis D is contact with infected blood or other bodily fluids. This can happen through sharing needles or drug materials with an infected person or having unprotected sex with an infected person. The signs and symptoms of HDV can include: yellow skin and eyes (jaundice), stomach upset, pain in your belly, throwing up, fatigue, loss of appetite, joint pain, dark urine, light-colored stool.

Read more about Hepatitis D (HDV) - Drug Pipeline Landscape here: https://www.globalinsightservices.com/reports/hepatitis-d-hdv-drug-pipeline-landscape-2022/

Report Highlights:

Global Insight Service's, Hepatitis D (HDV) - Drug Pipeline Landscape, 2022 report provides an overview of the Hepatitis D pipeline drugs. This report covers detailed insights on Hepatitis D (HDV) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Hepatitis D (HDV) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology:

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

To remain 'ahead' of your competitors, request for a sample: https://www.globalinsightservices.com/request-sample/GIS31055/

Scope:

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Key Players:

- Antios Therapeutics, Inc
- Eiger BioPharmaceuticals Inc
- Gilead Sciences Inc
- Hepatera Ltd.
- Janssen Research & Development, LLC
- PharmaEssentia
- Replicor Inc.

Get a Customized Scope to Match Your Need Ask an Expert: https://www.globalinsightservices.com/request-customization/GIS31055/

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.